Clinical trials: Irinotecan, completed
Lymph Node Metastasis, Cancer of Rectum and Anus
A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis
The goal of this clinical trial is to compare in newly diagnosed patients with resectable rectal cancer with lateral lymph node metastasis.
- Conditions
- Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin, Intestinal Neoplasms
- Trial name
- NCT06048146
- Testing
- Experimental: FOLFOXIRI and Lateral lymph node dissection, Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
Metastatic Colorectal Cancer
Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment…
- Trial name
- NCT05316818
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Kasr El Aini Hospital
Advanced Gastric Cancer
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Because well-designed, randomized, controlled clinical trials are lacking in patients with advanced gastric cancer (AGC), and because randomly allocating patients to treatments that do not accord with their preferences may…
- Trial name
- NCT00821990
- Testing
- Chemotherapy, Best supportive care
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
The outcome for children with high-grade gliomas and diffuse intrinsic brainstem gliomas remains poor despite the use of multi-modal therapy with surgery, radiation therapy and chemotherapy.
- Trial name
- NCT00890786
- Testing
- Temozolomide, Bevacizumab, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Advanced Solid Tumours
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents.
- Trial name
- AToM (NCT02588105)
- Testing
- AZD0156, Olaparib, irinotecan
- Where
- 5 sites in United States, South Korea and 2 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Metastatic Colorectal Cancer
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for…
- Trial name
- NCT05593328
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 27 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cardiff Oncology
Extensive Stage Small Cell Lung Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00057837
- Testing
- G-CSF, Cisplatin, Etoposide
- Where
- 79 sites in United States
- Volunteers
- 140 people
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic regimen.
- Trial name
- NCT03750669
- Testing
- AG regimen, mFolfirinox
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colon Cancer, Rectum Cancer
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
- Trial name
- NCT00336856
- Testing
- Cetuximab, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pittsburgh
Carcinoma, Hepatocellular
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
- Trial name
- NCT00635323
- Testing
- Irinotecan plus capecitabine
- Where
- 9 sites in China, Hong Kong and 2 more
- Volunteers
- 73 people
- Sponsor
- Pfizer
Pancreatic Cancer
Molecularly Tailored Therapy for Pancreas Cancer
Patient therapy is tailored according to the molecular profile of the patient's tumor.
- Trial name
- NCT01888978
- Testing
- Gem-OX, Gem-5FU, Gem-Tax
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Gastrointestinal Cancer, Carcinoma, Neuroendocrine
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Primary Objective: 1. Assess the clinical activity defined by response rate of irinotecan and cisplatin in untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.
- Trial name
- NCT00353015
- Testing
- Cisplatin, Irinotecan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT01091259
- Testing
- Irinotecan, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Metastatic Colorectal Cancer
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of response rate to conventional chemotherapy with the FOLFIRI regimen as first-line…
- Trial name
- NCT01219920
- Testing
- FOLFIRI, FOLFOXIRI
- Where
- 48 sites in Italy
- Volunteers
- 244 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
First Line Metastatic Colorectal Cancer
Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer
This prospective, non randomized multicenter phase II study, will determine the feasibility of individualized dose of irinotecan with the UGT1A1 polymorphism, in patients with metastatic colorectal cancer treated with FOLFIRI.
- Trial name
- IriGen (NCT01963182)
- Testing
- Irinotecan
- Where
- 3 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Jean Perrin
Brain and Central Nervous System Tumors
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004068
- Testing
- irinotecan hydrochloride, temozolomide, conventional surgery
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- St. Jude Children's Research Hospital
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma
- Trial name
- NCT00354835
- Testing
- Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride
- Where
- 226 sites in United States, Australia and 4 more
- Volunteers
- 481 people
- Sponsor
- Children's Oncology Group
Metastatic Colorectal Cancer
Biomarker Directed Treatment in Metastatic Colorectal Cancer
This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC).
- Trial name
- NCT01703390
- Testing
- FOLFIRI + Cetuximab, modifiedFOLFOX6 + Cetuximab
- Where
- 11 sites in Austria
- Volunteers
- 47 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Colorectal Cancer
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal…
- Trial name
- NCT00497497
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.